Business Description
Lincoln Pharmaceuticals Ltd
ISIN : INE405C01035
Compare
Compare
Traded in other countries / regions
531633.India IPO Date
2000-11-27Description
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 147.86 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 94.83 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 7.17 | |||||
| Beneish M-Score | -2.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.3 | |||||
| 3-Year EBITDA Growth Rate | 13.1 | |||||
| 3-Year EPS without NRI Growth Rate | 8.2 | |||||
| 3-Year FCF Growth Rate | -26.9 | |||||
| 3-Year Book Growth Rate | 17.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.77 | |||||
| 9-Day RSI | 48.41 | |||||
| 14-Day RSI | 44.79 | |||||
| 6-1 Month Momentum % | 14.09 | |||||
| 12-1 Month Momentum % | 1.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.34 | |||||
| Quick Ratio | 3.64 | |||||
| Cash Ratio | 1.66 | |||||
| Days Inventory | 97.17 | |||||
| Days Sales Outstanding | 106.2 | |||||
| Days Payable | 104.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.28 | |||||
| Dividend Payout Ratio | 0.04 | |||||
| Forward Dividend Yield % | 0.28 | |||||
| 5-Year Yield-on-Cost % | 0.28 | |||||
| Shareholder Yield % | 0.31 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.56 | |||||
| Operating Margin % | 14.89 | |||||
| Net Margin % | 16.43 | |||||
| FCF Margin % | 4.01 | |||||
| ROE % | 16.31 | |||||
| ROA % | 13.53 | |||||
| ROIC % | 15.13 | |||||
| ROC (Joel Greenblatt) % | 37.93 | |||||
| ROCE % | 20.54 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.19 | |||||
| PE Ratio without NRI | 13.19 | |||||
| Shiller PE Ratio | 18.44 | |||||
| Price-to-Owner-Earnings | 16.26 | |||||
| PEG Ratio | 0.99 | |||||
| PS Ratio | 2.18 | |||||
| PB Ratio | 2 | |||||
| Price-to-Tangible-Book | 2 | |||||
| Price-to-Free-Cash-Flow | 54.02 | |||||
| Price-to-Operating-Cash-Flow | 20.17 | |||||
| EV-to-EBIT | 8.6 | |||||
| EV-to-EBITDA | 7.85 | |||||
| EV-to-Revenue | 1.84 | |||||
| EV-to-FCF | 43.85 | |||||
| Price-to-Projected-FCF | 1.29 | |||||
| Price-to-DCF (Earnings Based) | 0.58 | |||||
| Price-to-DCF (FCF Based) | 2.08 | |||||
| Price-to-Median-PS-Value | 1.93 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.94 | |||||
| Price-to-Graham-Number | 1.08 | |||||
| Price-to-Net-Current-Asset-Value | 3.33 | |||||
| Price-to-Net-Cash | 21.3 | |||||
| Earnings Yield (Greenblatt) % | 11.63 | |||||
| FCF Yield % | 1.85 | |||||
| Forward Rate of Return (Yacktman) % | 16.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lincoln Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 5,881.058 | ||
| EPS (TTM) (₹) | 48.25 | ||
| Beta | 0.7 | ||
| Volatility % | 44.06 | ||
| 14-Day RSI | 44.79 | ||
| 14-Day ATR (₹) | 24.347609 | ||
| 20-Day SMA (₹) | 647.21 | ||
| 12-1 Month Momentum % | 1.35 | ||
| 52-Week Range (₹) | 498 - 814 | ||
| Shares Outstanding (Mil) | 20.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lincoln Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lincoln Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lincoln Pharmaceuticals Ltd Frequently Asked Questions
What is Lincoln Pharmaceuticals Ltd(BOM:531633)'s stock price today?
The current price of BOM:531633 is ₹636.60. The 52 week high of BOM:531633 is ₹814.00 and 52 week low is ₹498.00.
When is next earnings date of Lincoln Pharmaceuticals Ltd(BOM:531633)?
The next earnings date of Lincoln Pharmaceuticals Ltd(BOM:531633) is .
Does Lincoln Pharmaceuticals Ltd(BOM:531633) pay dividends? If so, how much?
The Dividend Yield %  of Lincoln Pharmaceuticals Ltd(BOM:531633) is 0.28% (As of Today), Highest Dividend Payout Ratio of Lincoln Pharmaceuticals Ltd(BOM:531633) was 0.12. The lowest was 0.04. And the median was 0.06. The  Forward Dividend Yield % of Lincoln Pharmaceuticals Ltd(BOM:531633) is 0.28%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers